Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00804310 · ClinicalTrials.gov registry record · Phase 1
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00804310: Clinical Trial Phase 1 study, sponsored by University of California, Davis.
NCT00804310 is a Phase 1 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00804310, a Phase 1 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with ixabepilone may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib given together with ixabepilone in treating patients with advanced solid tumors.
Primary Outcome
Assessed by NCI CTCAE v 3.0
Interventions
- DRUG lapatinib ditosylate
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Why NCT00804310 stopped before completion
NCT00804310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which lapatinib ditosylate is the first listed.
NCT00804310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00804310 about?
NCT00804310 is a clinical study titled "Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors". RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib t...
What is the current status of trial NCT00804310?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2009-08. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00804310?
The interventions under investigation include: lapatinib ditosylate (DRUG), ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00804310?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00804310's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia